ClinicalTrials.gg
RecruitingNCT06084416Updated Oct 13, 2026

A Study of Sovilnesib in Subjects With Ovarian Cancer

A Phase 1 interventional study of Sovilnesib in High Grade Serous Adenocarcinoma of Ovary, Fallopian Tube Cancer and Primary Peritoneal Carcinoma, sponsored by Volastra Therapeutics, Inc.. Recruiting at 11 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by Volastra Therapeutics, Inc. · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2024; still recruiting 2 years 7 months later.
Updated Oct 13, 2026Now RecruitingSite recruiting status changed+6 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 589 studies in Fallopian Tube Neoplasms with a site in United States — 61 open to participants now, 130 under way, 24 of them phase 3. Fallopian Tube Neoplasms · United States.

Planned enrollment
98th of 513
150 · median 40
Started
2024
with 13 others
Phase 1
181 of 589
14 open now
Primary completion
2027-11
later than 83 of 129 live
Registered
550th of 589
by date

Among the 589 studies in Fallopian Tube Neoplasms with a site in United States, this one is the 98th largest by planned enrollment of the 513 interventional ones that give a count, is one of 14 that started in 2024, is one of 181 in phase 1, reaches primary completion later than 83 of the 129 other live ones, and was the 550th registered.

Fallopian Tube Neoplasms

835 studies on the registry are indexed under Fallopian Tube Neoplasms; 128 are open to participants now.

Browse Fallopian Tube Neoplasms studies →

Open to participants now

61 of the 589 studies in Fallopian Tube Neoplasms with a site in United States are open now. Recruiting first, the newest first:

56 more — sign in →

All 61 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 104 Fallopian Tube Neoplasms studies recruiting now, 85 (82%) set no upper age limit and 10 (10%) stop at 75 or younger; 6 take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 589 studies in Fallopian Tube Neoplasms with a site in United States, or all of them as a file.
02

Study summary

This is a phase 1b study to assess the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of sovilnesib at different dose levels to establish the optimal dose of sovilnesib in subjects with selected advanced solid tumors.

Read the detailed description

This is a phase 1b study of sovilnesib in subjects with advanced solid tumors. The focus of the proposed clinical study is to establish the optimal dose of sovilnesib for further clinical development.

An adaptive multi-cohort design will be used to assess the safety, tolerability, PK, and efficacy of multiple dose levels in parallel to establish the RP2D of sovilnesib.

The study will be conducted in two parts: Part 1 and Part 2. Part 1 is a randomized dose optimization phase in the biomarker-unselected platinum resistant HGSOC patient population. Part 2 is a randomized dose optimization phase in the p16 positive (biomarker-selected) platinum resistant HGSOC patient population. Depending on the emerging data of the Part 1 dose optimization stage, consideration will be given to initiate sub-study cohort(s) in other selected locally advanced or metastatic tumor types to provide additional safety, PK/PD and preliminary efficacy data. Early stopping rules for safety based on a Bayesian Toxicity Monitoring Design and for futility based on a Bayesian Efficacy Monitoring via Predictive Probability Design will be applied.

Sovilnesib will be given orally in 28-day cycles at selected dose levels of interest. Dosing will continue until disease progression, unacceptable toxicity, withdrawal of consent, or other stopping criteria are met.

03

Conditions studied

  • High Grade Serous Adenocarcinoma of Ovary
  • Fallopian Tube Cancer
  • Primary Peritoneal Carcinoma
  • Chromosomal Instability

Keywords

  • KIF18A Inhibitor
04

Who can participate

The criteria were revised on the registry on Oct 13, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • All Parts: Age ≥ 18 years, Performance Status ≤ 1, at least 1 site of evaluable by CT scan or MRI per 1.1, able to take oral medication without alteration
  • confirmed locally advanced, inoperable, or tumor.
  • High Grade Serous Ovarian Cancer, Fallopian Tube or Primary Peritoneal Cancer - histologically confirmed; locally advanced, inoperable or metastatic; p16 positive (Part 2 only); platinum resistant (defined as radiographic progression/recurrence \<180 days after last dose of ≥ 4 cycles of platinum containing therapy) or ; prior bevacizumab treatment, unless ineligible or intolerant; if germline and/or somatic BRCA1/2 mutation, previously treated with PARP-inhibitor (unless ineligible or intolerant).

Key Exclusion Criteria:

  • Part 1 only: MSI-H, dMMR, POLE gene hotspot mutated, or known hypermutator phenotype
  • Endometrioid, clear cell, mucinous, sarcomatoid, low-grade/borderline ovarian tumor or mixed tumors containing any of the above histologies
  • Previously received KIF18A inhibitor
  • , or new or progressive or spinal cord compression
  • Cardiac parameters: MI, PE, CABG, severe/unstable angina or stroke ≤ 6 months, Class ≥ II, \< 50%
  • Any gastrointestinal condition (e.g. malabsorption syndrome, surgical anastomosis, short bowel syndrome) that might affect the absorption of oral medications including the study drug
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
150 participants (estimated)

Study arms

  • Experimental
    Dose Level 1

    Subjects will receive sovilnesib once daily at Dose Level 1 in 28-day cycles.

    Drug: Sovilnesib

  • Experimental
    Dose Level 2

    Subjects will receive sovilnesib once daily at Dose Level 2 in 28-day cycles.

    Drug: Sovilnesib

  • Experimental
    Dose Level 3

    Subjects will receive sovilnesib once daily at Dose Level 3 in 28-day cycles.

    Drug: Sovilnesib

  • Experimental
    Dose Level 4

    Subjects will receive sovilnesib once daily at Dose Level 4 in 28-day cycles.

    Drug: Sovilnesib

Interventions

  • DrugSovilnesib

    Sovilnesib tablets will be given orally.

06

What researchers measure

Primary outcomes

  1. Determination of the Recommended Phase 2 Dose (RP2D) of Sovilnesib

    Time frame: Up to 24 months

  2. Frequency and duration of Serious Adverse Events (SAEs) graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0

    Time frame: Up to 24 months

  3. Frequency and duration of Treatment-related Adverse Events (AEs) graded per NCI-CTCAE version 5.0

    Time frame: Up to 24 months

  4. Frequency and duration of Treatment-Emergent AEs (TEAEs) graded per NCI-CTCAE version 5.0

    Time frame: Up to 24 months

  5. Frequency of Dose Interruptions and Permanent Treatment Discontinuations

    Time frame: Up to 24 months

  6. Objective Response Rate (ORR) as assessed by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1

    Time frame: Up to 24 months

Secondary outcomes

  1. Duration of Response (DOR) as assessed by RECIST version 1.1

    Time frame: Up to 24 months

  2. Disease Control Rate (DCR) as assessed by RECIST version 1.1

    Time frame: Up to 24 months

  3. Progression Free Survival (PFS) as assessed by RECIST version 1.1

    Time frame: Up to 24 months

  4. Evaluation of CA-125 response by Gynecologic Cancer InterGroup (GCIG) criteria

    Time frame: Up to 24 months

  5. Overall Survival (OS) (Part 2 only)

    Time frame: Up to 24 months

  6. Plasma level of Sovilnesib

    Time frame: Up to 24 months

07

Study locations

4 of 11 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2024 (actual). Primary completion is estimated for Nov 2027, 43 months after the start.

Of 31 industry-sponsored phase 1 interventional studies under Fallopian Tube Neoplasms, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 57. This study's planned 43 months is close to that.

Counting every sponsor, half of 97 studies reached it within 54 months; a quarter within 36 and three quarters within 83.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 13, 2026: primary completion Mar 2026 → Nov 2027 and completion Apr 2026 → Dec 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 10, 2023
First posted
Oct 16, 2023
StartActual
Apr 4, 2024
Primary completionEst.
Nov 2027was Mar 2026
CompletionEst.
Dec 2027was Apr 2026
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Recruiting
changed Oct 13, 2026
Sites
2 sites removed. 11 sites changed recruiting status (7 now active, not recruiting, 4 now recruiting)
Show 11 sites
  • The University of Alabama at Birmingham · Birmingham, United Statesno status→Recruiting
  • University of Arkansas for Medical Sciences · Little Rock, United Statesno status→Active, not recruiting
  • Hoag Memorial Hospital · Newport Beach, United Statesno status→Active, not recruiting
  • Georgia Cancer Center Augusta University · Atlanta, United Statesno status→Recruiting
  • Johns Hopkins Hospital · Baltimore, United Statesno status→Active, not recruiting
  • Dana Farber Cancer Institute · Boston, United Statesno status→Active, not recruiting
  • Roswell Park Comprehensive Cancer Center · Buffalo, United Statesno status→Recruiting
  • Icahn School of Medicine at Mount Sinai · New York, United Statesno status→Active, not recruiting
  • OU Health Stephenson Cancer Center · Oklahoma City, United Statesno status→Recruiting
  • MUSC Hollings Cancer Center · Charleston, United Statesno status→Active, not recruiting
  • Fred Hutchinson Cancer Center · Seattle, United Statesno status→Active, not recruiting
Show 2 removed
  • UCLA · Los Angeles, United States
  • Corewell Health · Grand Rapids, United States
Oct 13, 2026
Primary completion
Mar 2026→Nov 2027
Oct 13, 2026
Study completion
Apr 2026→Dec 2027
Oct 13, 2026
Enrollment
120→150
Oct 13, 2026
Eligibility
Sex FEMALE→ALL; 4 criteria edited, 1 added
What changed in the criteria
  • AddedHistologically confirmed locally advanced, inoperable, or metastatic tumor.
  • EditedHigh Grade Serous Ovarian Cancer, Fallopian Tube or Primary Peritoneal Cancer - histologically or cytologically confirmed; metastaticlocally advanced, inoperable or unresectablemetastatic; p16 positive (Part 2 only); platinum resistant (defined as radiographic progression/recurrence within 6 months<180 days after last dose of ≥ 4 cycles of platinum containing therapy) or platinum refractory; prior bevacizumab treatment, orunless ineligible or intolerant to bevacizumab, or did not receive bevacizumab based on Investigator judgement; if germline and/or somatic BRCA1/2 mutation, previously treated with PARP-inhibitor or(unless ineligible or intolerant).
  • EditedPart 1 only: MSI-H, dMMR, POLE gene hotspot mutated, or known hypermutator phenotype
  • ChangedBefore Current CNS metastases or leptomeningeal diseaseNow Leptomeningeal disease, or new or progressive CNS metastases or spinal cord compression
  • EditedCardiac parameters: MI, PE, CABG, severe/unstable angina or stroke ≤ 6 months, unstable angina/PE/DVT/CABG ≤ 6 months, NYHA Class ≥ II, LVEF < 50%
Oct 13, 2026
Secondary outcomes
1 added
What changed in the outcomes
  • AddedOverall Survival (OS) (Part 2 only)Time frame: Up to 24 months
Oct 13, 2026
Contact
Study contact now listed: added c•••@volastratx.com · •••1248. See the current contact
Oct 13, 2026
Site contacts
Changed at 4 sites. See the sites
Show 4 sites
  • The University of Alabama at Birmingham · Birmingham, United StatesContact added •••4986
  • Georgia Cancer Center Augusta University · Atlanta, United StatesContact added g•••@augusta.edu · •••3473
  • Roswell Park Comprehensive Cancer Center · Buffalo, United StatesContact added a•••@roswellpark.org · •••7724
  • OU Health Stephenson Cancer Center · Oklahoma City, United StatesContact added c•••@ouhsc.edu · •••8707
Oct 13, 2026
Show all 1 update
  1. Oct 13, 2026
    Active, not recruiting→Recruiting
    2 sites removed. 11 sites changed recruiting status (7 now active, not recruiting, 4 now recruiting)
    Show 11 sites
    • The University of Alabama at Birmingham · Birmingham, United Statesno status→Recruiting
    • University of Arkansas for Medical Sciences · Little Rock, United Statesno status→Active, not recruiting
    • Hoag Memorial Hospital · Newport Beach, United Statesno status→Active, not recruiting
    • Georgia Cancer Center Augusta University · Atlanta, United Statesno status→Recruiting
    • Johns Hopkins Hospital · Baltimore, United Statesno status→Active, not recruiting
    • Dana Farber Cancer Institute · Boston, United Statesno status→Active, not recruiting
    • Roswell Park Comprehensive Cancer Center · Buffalo, United Statesno status→Recruiting
    • Icahn School of Medicine at Mount Sinai · New York, United Statesno status→Active, not recruiting
    • OU Health Stephenson Cancer Center · Oklahoma City, United Statesno status→Recruiting
    • MUSC Hollings Cancer Center · Charleston, United Statesno status→Active, not recruiting
    • Fred Hutchinson Cancer Center · Seattle, United Statesno status→Active, not recruiting
    Show 2 removed
    • UCLA · Los Angeles, United States
    • Corewell Health · Grand Rapids, United States
    Primary completion Mar 2026→Nov 2027
    Study completion Apr 2026→Dec 2027
    Enrollment 120→150
    Eligibility Sex FEMALE→ALL; 4 criteria edited, 1 added
    What changed in the criteria
    • AddedHistologically confirmed locally advanced, inoperable, or metastatic tumor.
    • EditedHigh Grade Serous Ovarian Cancer, Fallopian Tube or Primary Peritoneal Cancer - histologically or cytologically confirmed; metastaticlocally advanced, inoperable or unresectablemetastatic; p16 positive (Part 2 only); platinum resistant (defined as radiographic progression/recurrence within 6 months<180 days after last dose of ≥ 4 cycles of platinum containing therapy) or platinum refractory; prior bevacizumab treatment, orunless ineligible or intolerant to bevacizumab, or did not receive bevacizumab based on Investigator judgement; if germline and/or somatic BRCA1/2 mutation, previously treated with PARP-inhibitor or(unless ineligible or intolerant).
    • EditedPart 1 only: MSI-H, dMMR, POLE gene hotspot mutated, or known hypermutator phenotype
    • ChangedBefore Current CNS metastases or leptomeningeal diseaseNow Leptomeningeal disease, or new or progressive CNS metastases or spinal cord compression
    • EditedCardiac parameters: MI, PE, CABG, severe/unstable angina or stroke ≤ 6 months, unstable angina/PE/DVT/CABG ≤ 6 months, NYHA Class ≥ II, LVEF < 50%
    Secondary outcomes 1 added
    What changed in the outcomes
    • AddedOverall Survival (OS) (Part 2 only)Time frame: Up to 24 months
    Contact Study contact now listed: added c•••@volastratx.com · •••1248. See the current contact
    Site contacts Changed at 4 sites. See the sites
    Show 4 sites
    • The University of Alabama at Birmingham · Birmingham, United StatesContact added •••4986
    • Georgia Cancer Center Augusta University · Atlanta, United StatesContact added g•••@augusta.edu · •••3473
    • Roswell Park Comprehensive Cancer Center · Buffalo, United StatesContact added a•••@roswellpark.org · •••7724
    • OU Health Stephenson Cancer Center · Oklahoma City, United StatesContact added c•••@ouhsc.edu · •••8707
    + 4 other changes: identifiers, verification date, oversight details and description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06084416
Lead sponsor
Volastra Therapeutics, Inc.
Responsible party
Sponsor
First posted
Oct 16, 2023
Start date
Apr 4, 2024
Primary completion
Nov 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Oct 13, 2026

Study contacts

Volastra Therapeutics, Inc.
Contact
clinicaltrials@volastratx.com
(646) 344-1248

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion